Vosoritide Acetate Raw Powder CAS 1480724-61-5

In the European Union, Vosoritide acetate raw powder is indicated for the treatment of achondroplasia in people two years of age and older whose epiphyses are not closed.

In the United States, vosoritide is indicated to increase growth in children five years of age and older with achondroplasia and open epiphyses (growth plates)
If you need it, pls click e-mail sales1@faithfulbio.com

Result

Appearance

White to off-white powder

conforms

conforms

Assay(By HPLC)

95% min

99.1%

Vosoritide works by binding to a receptor (target) called natriuretic peptide receptor type B (NPR-B), which reduces the activity of fibroblast growth factor receptor 3 (FGFR3).FGFR3 is a receptor that normally down-regulates cartilage and bone growth when activated by one of the proteins known as acidic and basic fibroblast growth factor. It does so by inhibiting the development (cell proliferation and differentiation) of chondrocytes, the cells that produce and maintain the cartilaginous matrix which is also necessary for bone growth. Children with achondroplasia have one of several possible FGFR3 mutations resulting in constitutive (permanent) activity of this receptor, resulting in overall reduced chondrocyte activity and thus bone growth.